Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

Diabetologia

Volumn 48, Issue 4, 2005, Pages 612-615

  Holst, J J ^a   Deacon, C F ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Dipeptidyl peptidase IV; Gastric inhibitory polypeptide; Gastroenteropancreatic peptide hormones; Glucagon like peptide 1; Incretin; Incretin effect; Oral hypoglycaemic agents; Pharmacokinetics; Proteolytic processing

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTROINTESTINAL HORMONE; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN MIMETIC; UNCLASSIFIED DRUG;

CONCENTRATION (PARAMETERS); DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GLUCOSE HOMEOSTASIS; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MEAL; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STOMACH EMPTYING;

ADENOSINE DEAMINASE; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLYCOPROTEINS; HOMEOSTASIS; HUMANS; MODELS, BIOLOGICAL; NAUSEA; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; VOMITING;

EID: 17844399596     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1705-7     Document Type: Review

References (34)

1. Nauck MA, El-Ouaghlidi (2005) The therapeutic actions of DPP-IV are not mediated by glucagon-like peptide-1. Diabetologia DOI 10.1007/s00125-005-1704-8
2. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131
3. Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957
4. Holst JJ, Deacon CF (1998) Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663-1670
5. Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835
6. Mentlein R (1999) Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 85:9-24
7. Vilsboll T, Holst JJ (2004) Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 47:357-366
8. Vilsboll T, Krarup T, Madsbad S, Holst JJ (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45:1111-1119
9. Hansotia T, Baggio LL, Delmeire D et al (2004) Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53:1326-1335
10. Ahren B, Simonsson E, Larsson H et al (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875
11. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084
12. Ahren B, Gomis R, Standl E, Mills D, Schweizer A (2004) Prolonged efficacy of LAF237 in patients with type 2 diabetes (T2DM) inadequately treated with metformin. Diabetes 53:7L-B
13. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613
14. Hansen L, Deacon CF, Orskov C, Holst JJ (1999) Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356-5363
15. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jørgensen PN, Holst JJ (2000) Somatostatin restrains the secretion of glucagon-like peptide-1 and 2 from isolated perfused porcine ileum. Am J Physiol 278:E1010-E1018
16. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 2713:E458-E464
17. Holst JJ (2003) Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Adv Exp Med Biol 524:263-279
18. Nakagawa A, Satake H, Nakabayashi H et al (2004) Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 110:36-43
19. Nishizawa M, Nakabayashi H, Uchida K, Nakagawa A, Niijima A (1996) The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J Auton Nerv Syst 61:149-154
20. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A (1996) Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 271:E808-E813
21. Balkan B, Li X (2000) Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279:R1449-R1454
22. Meier JJ, Gallwitz B, Salmen S et al (2003) Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719-2725
23. El-Ouaghlidi A, Rehring E, Schweizer A, Holmes D, Nauck MA (2003) The dipeptidyl peptidase IV inhibitor LAF237 does not accentuate reactive hypoglyaemia caused by the sulfonylurea glibenclamide administered before an oral glucose load in healthy subjects (abstract 507-P). Diabetes 52(Suppl 1):A118
24. Orskov C, Poulsen SS, Moller M, Holst JJ (1996) Glucagon-like peptide I receptors in the subfomical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45:832-835
25. Tang-Christensen M, Vrang N, Larsen PJ (2001) Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord 25(Suppl 5):S42-S47
26. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ (2002) Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172:355-362
27. Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB (1996) Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM) - evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135:425-432
28. Toft-Nielsen M-B, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723
29. Lynn FC, Thompson SA, Pospisilik JA et al (2003) A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. FASEB J 17:91-93
30. Meneilly GS, Bryer-Ash M, Elahi D (1993) The effect of glyburide on beta-cell sensitivity to glucose- dependent insulinotropic polypeptide. Diabetes Care 16:110-114
31. Kjems LL, Holst JJ, Volund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380-386
32. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA (1996) Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19:580-586
33. Burcelin R, Da Costa A, Drucker D, Thorens B (2001) Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50:1720-1728
34. Dardevet D, Moore MC, Neal D, DiCostanzo CA, Snead W, Cherrington AD (2004) Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am J Physiol Endocrinol Metab 287:E75-E81